Acute pancreatitis is a rare complication after percutaneous mechanical thrombectomy in treatment of thrombotic disorders. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient/procedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.
Percutaneous mechanical thrombectomy (PMT) has seen increasing utilization in the management of acute thrombotic events within both arterial and venous systems. The rheolytic thrombectomy such as AngioJet system employs hydrodynamic principles to disrupt and remove thrombus. The efficacy and safety have been demonstrated across various vascular diseases, including deep venous thrombosis (DVT), peripheral arterial occlusions, and dialysis access thrombosis, establishing PMT as a valuable minimally invasive therapeutic option. Acute pancreatitis is a serious inflammatory condition commonly associated with gallstones, alcohol consumption, hyperlipidemia, or metabolic disorders. Only isolated case reports have documented this complication following PMT. Despite the well-documented occurrence of other procedure-related adverse events, such as bradycardia, hemoglobinuria, and renal impairment, pancreatitis remains an exceptionally rare and under-recognized complication. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient/procedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.
Study Type
OBSERVATIONAL
Enrollment
10
Renji Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGIncidence of acute pancreatitis
The incidence of acute pancreatitis within 14 days after mechanical thrombectomy for peripheral thromboembolic disease.
Time frame: Within 14 days
Incidence of acute severe pancreatitis
The incidence of acute severe pancreatitis within 14 days after mechanical thrombectomy for peripheral thromboembolic disease.
Time frame: Within 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.